Addiction to Prescription Opioids: Characteristics of the Emerging Epidemic and Treatment With Buprenorphine

Experimental and Clinical Psychopharmacology

Volumn 16, Issue 5, 2008, Pages 435-441

  Mendelson, John ^a   Flower, Keith ^a   Pletcher, Mark J ^b   Galloway, Gantt P ^a  

^a Pacific Medical Center Research Institute St Luke's Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

addiction; buprenorphine; opiate; opioid; prescription

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CODEINE; DIAMORPHINE; HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; LEVACETYLMETHADOL; METHADONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; OPIATE; OXYCODONE;

ARTICLE; DRUG DOSE ESCALATION; EPIDEMIC; HUMAN; OPIATE ADDICTION; PAIN; PHYSICIAN ATTITUDE; PRESCRIPTION; TREATMENT OUTCOME;

ANALGESICS, OPIOID; BUPRENORPHINE; DISEASE OUTBREAKS; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN; PRESCRIPTION DRUGS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 54049105404     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0013637     Document Type: Article

References (51)

1. Amass L., Ling W., Freese T.E., Reiber C., Annon J.J., Cohen A.J., et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. The American Journal on Addictions 13 (2004) S42-66
2. Ballantyne J.C., and LaForge K.S. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129 (2007) 235-255
3. Barry D.T., Moore B.A., Pantalon M.V., Chawarski M.C., Sullivan L.E., O'Connor P.G., et al. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. Journal of General Internal Medicine 22 (2007) 242-245
4. Becker W.C., Fiellin D.A., Merrill J.O., Schulman B., Finkelstein R., Olsen Y., et al. Opioid use disorder in the United States: Insurance status and treatment access. Drug and Alcohol Dependence 94 (2008) 207-213
5. Becker W.C., Sullivan L.E., Tetrault J.M., Desai R.A., Fiellen D.A., et al. Non-medical use, abuse and dependence on prescription opioids among US adults: Psychiatric, medical and substance use correlates. Drug and Alcohol Dependence 94 (2008) 38-47
6. Brands B., Blake J., Sproule B., Gourlay D., and Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug and Alcohol Dependence 73 (2004) 199-207
7. Caldiero R.M., Parran Jr. T.V., Adelman C.L., and Piche B. Inpatient initiation of buprenorphine maintenance vs. detoxification: Can retention of opioid-dependent patients in outpatient counseling be improved?. The American Journal on Addictions 15 (2006) 1-7
8. Carise D., Dugosh K.L., McLellan A.T., Camilleri A., Woody G.E., and Lynch K.G. Prescription OxyContin abuse among patients entering addiction treatment. American Journal of Psychiatry 164 (2007) 1750-1756
9. Cicero T.J., Inciardi J.A., and Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. The Journal of Pain: Official Journal of the American Pain Society 6 (2005) 662-672
10. Comer S.D., Sullivan M.A., Yu E., Rothenberg J.L., Kleber H.D., Kampman K., et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Archives of General Psychiatry 63 (2006) 210-218
11. Compton P., Darakjian J., and Miotto K. Screening for addiction in patients with chronic pain and "problematic" substance use: Evaluation of a pilot assessment tool. Journal of Pain and Symptom Management 16 (1998) 355-363
12. Cunningham C.O., Kunins H.V., Roose R.J., Elam R.T., and Sohler N.L. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. Journal of General Internal Medicine 22 (2007) 1325-1329
13. Dahan A. Opioid-induced respiratory effects: New data on buprenorphine. Palliative Medicine 20 (2006) 3-8
14. Davis W.R., and Johnson B.D. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug and Alcohol Dependence 92 (2008) 267-276
15. DAWN (U.S. Drug Abuse Warning Network). U.S. Substance Abuse and Mental Health Services Administration Drug Abuse Warning Network (2005) from dawninfo.samhsa.gov/files/DAWN2k5ED.htm#Tab1
16. Fiellin D.A., Pantalon M.V., Chawarski M.C., Moore B.A., Sullivan L.E., O'Connor P.G., et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. The New England Journal of Medicine 355 (2006) 365-374
17. Greenwald M.K., Johanson C.E., Moody D.E., Woods J.H., Kilbourn M.R., Koeppe R.A., et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28 (2003) 2000-2009
18. Horgan C.M., Reif S., Hodgkin D., Garnick D.W., and Merrick E.L. Availability of addiction medications in private health plans. Journal of Substance Abuse Treatment 34 (2008) 147-156
19. Kosten T.R., and Fiellin D.A. Buprenorphine for office-based practice: consensus conference overview. The American Journal of Addictions 13 Supplement 1 (2004) S1-7
20. Levy M.S. An exploratory study of OxyContin use among individuals with substance use disorders. Journal of Psychoactive Drugs 39 (2007) 271-276
21. Longo L.P., Parran Jr. T., Johnson B., and Kinsey W. Addiction: Part II. Identification and management of the drug-seeking patient. American Family Physician 61 (2000) 2401-2408
22. McCabe S.E., Teter C.J., Boyd C.J., Knight J.R., and Wechsler H. Nonmedical use of prescription opioids among U.S. college students: Prevalence and correlates from a national survey. Addictive Behaviors 30 (2005) 789-805
23. McCance-Katz E.F. Office-based buprenorphine treatment for opioid-dependent patients. Harvard Review of Psychiatry 12 (2004) 321-338
24. Merrill J.O., Jackson T.R., Schulman B.A., Saxon A.J., Awan A., Kapitan S., et al. Methadone medical maintenance in primary care. An implementation evaluation. Journal of General Internal Medicine 20 (2005) 344-349
25. Minozzi S., Amato L., Vecchi S., Davoli M., Kirchmayer U., and Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews, CD001333 (2006)
26. Mintzer I.L., Eisenberg M., Terra M., MacVane C., Himmelstein D.U., and Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Annals of Family Medicine 5 (2007) 146-150
27. Moore B.A., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., et al. Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. Journal of General Internal Medicine 22 (2007) 527-530
28. National Pain Foundation. National Pain Awareness Campaign: Questions and Answers on Pain (2007). http://www.painconnection.org/NationalPainAwareness/Factsheet.pdf from www.painconnection.org/NationalPainAwareness/Factsheet.pdf
29. Parran Jr. T. Prescription drug abuse. A question of balance. The Medical Clinics of North America 81 (1997) 967-978
30. Passik S.D., Kirsh K.L., Whitcomb L., Portenoy R.K., Katz N.P., Kleinman L., et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clinical Therapeutics 26 (2004) 552-561
31. Pletcher M.J., Kertesz S.G., Kohn M.A., and Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in U.S. emergency departments. The Journal of the American Medical Association 299 (2008) 70-78
32. Rapeli P., Fabritius C., Alho H., Salaspuro M., Wahlbeck K., and Kalska H. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: A naturalistic comparison of cognitive performance relative to healthy controls. BMC Clinical Pharmacology 7 (2007) 5
33. Rosenblum A., Parrino M., Schnoll S.H., Fong C., Maxwell C., Cleland C.M., et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug and Alcohol Dependence 90 (2007) 64-71
34. SAMHSA, NSDUH. (U.S. Substance Abuse and Mental Health Services Administration). How young adults obtain prescription pain relievers for nonmedical use. National Survey on Drug Use and Health (NSDUH) (2005). http://www.oas.samhsa.gov/2k6/getPain/getPain.htm 2005, from www.oas.samhsa.gov/2k6/getPain/getPain.htm
35. SAMHSA. (U.S. Substance Abuse and Mental Health Services Administration). National Survey on Drug Use and Health: Detailed Tables-Tables 4.1a-4.4a and 4.10a (2004). http://www.oas.samhsa.gov/NSDUH/2k4nsduh/2k4tabs/Sect4peTabs1to50.htm from www.oas.samhsa.gov/NSDUH/2k4nsduh/2k4tabs/Sect4peTabs1to50.htm
36. SAMHSA. (U.S. Substance Abuse and Mental Health Services Administration). (2006). National Survey on Drug Use and Health (NSDUH). Washington, D. C., from www.oas.samhsa.gov/nsduh/2k6nsduh/2k6Results.cfm#TOC
37. SAMHSA. (U.S. Substance Abuse and Mental Health Services Administration). National Survey on Drug Use and Health (NSDUH): Detailed Tables-Table 4.13b (2006). http://www.oas.samhsa.gov/NSDUH/2k6nsduh/tabs/Sect4peTabs1to16.htm from www.oas.samhsa.gov/NSDUH/2k6nsduh/tabs/Sect4peTabs1to16.htm
38. SAMHSA. (U.S. Substance Abuse and Mental Health Services Administration). National Survey on Drug Use and Health (NSDUH): Detailed Tables-Table 1.1a (2006). http://www.oas.samhsa.gov/HSDUH/2k6NSDUH/tabs/Sect1peTabs1to46.htm from www.oas.samhsa.gov/HSDUH/2k6NSDUH/tabs/Sect1peTabs1to46.htm
39. SAMHSA. (U.S. Substance Abuse and Mental Health Services Administration). National Survey on Drug Use and Health (NSDUH): Detailed Tables-Table 5.2a (2006). http://www.oas.samhsa.gov/NSDUH/2k6nsduh/tabs/Sect5peTabs1to56.htm from www.oas.samhsa.gov/NSDUH/2k6nsduh/tabs/Sect5peTabs1to56.htm
40. Shirayama Y., Ishida H., Iwata M., Hazama G.I., Kawahara R., and Duman R.S. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. Journal of Neurochemistry 90 (2004) 1258-1268
41. Sigmon S.C. Characterizing the emerging population of prescription opioid abusers. American Journal on Addictions 15 (2006) 208-212
42. Sorensen J.L., Trier M., Brummett S., Gold M.L., and Dumontet R. Withdrawal from methadone maintenance. Impact of a tapering network support program. Journal of Substance Abuse Treatment 9 (1992) 21-26
43. Stanton A., McLeod C., Luckey B., Kissin W.B., and Sonnefeld L.J. SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program, SAMHSA (US Substance Abuse and Mental Health Services Administration) (2006). http://www.buprenorphine.samhsa.gov/ASAM_06_Final_Results.pdf from www.buprenorphine.samhsa.gov/ASAM_06_Final_Results.pdf
44. Sullivan L.E., Chawarski M., O'Connor P.G., Schottenfeld R.S., and Fiellin D.A. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment?. Drug and Alcohol Dependence 79 (2005) 113-116
45. Sullivan L.E., Moore B.A., Chawarski M.C., Pantalon M.V., Barry D., O'Connor P.G., et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Journal of Substance Abuse Treatment 35 (2007) 87-92
46. TEDS. (U.S. Substance Abuse and Mental Health Services Administration). Treatment Episode Data Set 2005 (2005). http://www.dasis.samhsa.gov/teds05/TEDSAd2k5Index.htm from www.dasis.samhsa.gov/teds05/TEDSAd2k5Index.htm
47. United States Food and Drug Administration. Letter to Roxane Laboratories (2001). http://www.fda.gov/cder/foi/appletter/2001/20315S6LTR.PDF Retrieved Feb 9, 2008, from http://www.fda.gov/cder/foi/appletter/2001/20315S6LTR.PDF
48. Wasan A.D., Correll D.J., Kissin I., O'Shea S., and Jamison R.N. Iatrogenic addiction in patients treated for acute or subacute pain: A systematic review. Journal of Opioid Management 2 (2006) 16-22
49. Wedam E.F., Bigelow G.E., Johnson R.E., Nuzzo P.A., and Haigney M.C. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Archives of Internal Medicine 167 (2007) 2469-2475
50. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., and Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug and Alcohol Dependence 69 (2003) 215-232
51. Zhang H., Shi Y.G., Woods J.H., Watson S.J., and Ko M.C. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: Behavioral and BDNF mRNA expression studies. European Journal of Pharmacology 570 (2007) 89-96